196 related articles for article (PubMed ID: 34549308)
21. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
[TBL] [Abstract][Full Text] [Related]
22. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer.
Chu S; Liu G; Xia P; Chen G; Shi F; Yi T; Zhou H
Oncol Rep; 2017 Oct; 38(4):2401-2407. PubMed ID: 28765915
[TBL] [Abstract][Full Text] [Related]
23. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Hu D; Li M; Su J; Miao K; Qiu X
Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
[TBL] [Abstract][Full Text] [Related]
24. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1.
Gao HX; Yan L; Li C; Zhao LM; Liu W
Mol Med Rep; 2016 Nov; 14(5):4135-4143. PubMed ID: 27666124
[TBL] [Abstract][Full Text] [Related]
25. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.
Yu J; Xie F; Bao X; Chen W; Xu Q
Mol Cancer; 2014 May; 13():121. PubMed ID: 24885626
[TBL] [Abstract][Full Text] [Related]
26. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway.
Wang J; Liang S; Duan X
J Cell Biochem; 2019 Jun; 120(6):9539-9546. PubMed ID: 30525231
[TBL] [Abstract][Full Text] [Related]
28. miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.
Wu Z; Li X; Cai X; Huang C; Zheng M
Tumour Biol; 2016 Jun; 37(6):7939-50. PubMed ID: 26700673
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer.
Tang CP; Zhou HJ; Qin J; Luo Y; Zhang T
Oncol Rep; 2017 Nov; 38(5):3144-3152. PubMed ID: 29048659
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of microRNA-190 inhibits migration, invasion, epithelial-mesenchymal transition, and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer.
Sun G; Liu M; Han H
J Cell Physiol; 2019 Aug; 234(10):17824-17838. PubMed ID: 30993707
[TBL] [Abstract][Full Text] [Related]
31. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway.
Zhang M; Wang Y; Jiang L; Song X; Zheng A; Gao H; Wei M; Zhao L
J Exp Clin Cancer Res; 2021 Jan; 40(1):41. PubMed ID: 33494806
[TBL] [Abstract][Full Text] [Related]
32. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
33. lncRNA VIM‑AS1 promotes cell proliferation, metastasis and epithelial‑mesenchymal transition by activating the Wnt/β‑catenin pathway in gastric cancer.
Sun JG; Li XB; Yin RH; Li XF
Mol Med Rep; 2020 Dec; 22(6):4567-4578. PubMed ID: 33173977
[TBL] [Abstract][Full Text] [Related]
34. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
35. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
36. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
[TBL] [Abstract][Full Text] [Related]
37. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
39. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
